Published in Arch Neurol on January 01, 2006
Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med (2010) 13.57
Clan genomics and the complex architecture of human disease. Cell (2011) 4.53
Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease. Hum Genet (2013) 2.44
Targeted Next-Generation Sequencing for Clinical Diagnosis of 561 Mendelian Diseases. PLoS One (2015) 2.05
Compound heterozygosity for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral neuropathy. Am J Hum Genet (2010) 1.96
Digenic inheritance in medical genetics. J Med Genet (2013) 1.38
PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies. Orphanet J Rare Dis (2014) 1.00
Achromatopsia: the CNGB3 p.T383fsX mutation results from a founder effect and is responsible for the visual phenotype in the original report of uniparental disomy 14. Hum Genet (2007) 0.96
Mutation screening of mitofusin 2 in Charcot-Marie-Tooth disease type 2. J Neurol (2011) 0.95
Facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth neuropathy 1A - evidence for "double trouble" overlapping syndromes. BMC Med Genet (2013) 0.91
A complex phenotype of peripheral neuropathy, myopathy, hoarseness, and hearing loss is linked to an autosomal dominant mutation in MYH14. Hum Mutat (2011) 0.84
Myotonic dystrophy type I combined with X-linked dominant Charcot-Marie-Tooth neuropathy. Neurogenetics (2010) 0.84
Comprehensive Molecular Diagnosis of a Large Chinese Leber Congenital Amaurosis Cohort. Invest Ophthalmol Vis Sci (2015) 0.81
Compound Charcot-Marie-Tooth disease may determine unusual and milder phenotypes. Neurogenetics (2009) 0.78
Coexistent Charcot-Marie-Tooth type 1A and type 2 diabetes mellitus neuropathies in a Chinese family. Neural Regen Res (2015) 0.77
A patient with PMP22-related hereditary neuropathy and DBH-gene-related dysautonomia. J Neurol (2015) 0.76
Myotonic dystrophy-1 complicated by factor-v (leiden) mutation. Case Rep Med (2015) 0.75
Co-segregation of a homozygous SMN1 deletion and a heterozygous PMP22 duplication in a patient. Clin Case Rep (2016) 0.75
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance. Cell (2010) 4.37
GeneTests-GeneClinics: genetic testing information for a growing audience. Hum Mutat (2002) 2.97
Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry (2002) 2.86
The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol (2010) 2.19
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet (2011) 2.02
Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol (2008) 1.89
Genomic rearrangements resulting in PLP1 deletion occur by nonhomologous end joining and cause different dysmyelinating phenotypes in males and females. Am J Hum Genet (2002) 1.88
Prion protein codon 129 genotype prevalence is altered in primary progressive aphasia. Ann Neurol (2005) 1.83
Impact of presymptomatic genetic testing for hereditary ataxia and neuromuscular disorders. Arch Neurol (2004) 1.82
APOE and other loci affect age-at-onset in Alzheimer's disease families with PS2 mutation. Am J Med Genet B Neuropsychiatr Genet (2005) 1.80
Presence of alanine-to-valine substitutions in myofibrillogenesis regulator 1 in paroxysmal nonkinesigenic dyskinesia: confirmation in 2 kindreds. Arch Neurol (2005) 1.78
Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. J Opioid Manag (2009) 1.74
Missense mutations in the copper transporter gene ATP7A cause X-linked distal hereditary motor neuropathy. Am J Hum Genet (2010) 1.70
Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol (2010) 1.68
Mutations in SEPT9 cause hereditary neuralgic amyotrophy. Nat Genet (2005) 1.68
Pain in persons with postpolio syndrome: frequency, intensity, and impact. Arch Phys Med Rehabil (2008) 1.59
Hereditary ataxias: overview. Genet Med (2013) 1.58
Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J (2012) 1.53
Evidence for a novel late-onset Alzheimer disease locus on chromosome 19p13.2. Am J Hum Genet (2004) 1.51
Gain-of-function ADCY5 mutations in familial dyskinesia with facial myokymia. Ann Neurol (2014) 1.47
Autosomal dominant familial dyskinesia and facial myokymia: single exome sequencing identifies a mutation in adenylyl cyclase 5. Arch Neurol (2012) 1.46
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46
The N141I mutation in PSEN2: implications for the quintessential case of Alzheimer disease. Arch Neurol (2010) 1.46
Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain (2010) 1.45
An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann Neurol (2002) 1.44
Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. Arch Neurol (2006) 1.42
New clinical end points in rehabilitation medicine: tools for measuring quality of life. Am J Hosp Palliat Care (2009) 1.42
Missense mutations in the regulatory domain of PKC gamma: a new mechanism for dominant nonepisodic cerebellar ataxia. Am J Hum Genet (2003) 1.36
Falls in multiple sclerosis. PM R (2011) 1.36
Assessment of pain and health-related quality of life in slowly progressive neuromuscular disease. Am J Hosp Palliat Care (2002) 1.30
LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet (2006) 1.26
A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions. Acta Neuropathol (2008) 1.25
High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood (2003) 1.25
TREM2 and neurodegenerative disease. N Engl J Med (2013) 1.25
Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. Hum Mutat (2012) 1.25
Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. Am J Pathol (2009) 1.24
Clinicopathological concordance and discordance in three monozygotic twin pairs with familial Alzheimer's disease. J Neurol Neurosurg Psychiatry (2007) 1.22
Chronic pain in a large community sample of persons with multiple sclerosis. Mult Scler (2003) 1.22
Chronic pain in persons with neuromuscular disease. Arch Phys Med Rehabil (2005) 1.22
Fatigue and psychiatric illness in a large community sample of persons with multiple sclerosis. J Psychosom Res (2005) 1.21
Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag (2009) 1.21
IFRD1 is a candidate gene for SMNA on chromosome 7q22-q23. Am J Hum Genet (2009) 1.21
Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant (2003) 1.18
Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve (2008) 1.15
Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia. Hum Mol Genet (2006) 1.13
Chronic pain in persons with myotonic dystrophy and facioscapulohumeral dystrophy. Arch Phys Med Rehabil (2008) 1.13
Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype. Ann Neurol (2011) 1.13
Hypnotic analgesia for chronic pain in persons with disabilities: a case series. Int J Clin Exp Hypn (2005) 1.11
Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care (2004) 1.11
Quality improvement in neurology: amyotrophic lateral sclerosis quality measures: report of the quality measurement and reporting subcommittee of the American Academy of Neurology. Neurology (2013) 1.10
Exercise and rehabilitation for individuals with multiple sclerosis. Phys Med Rehabil Clin N Am (2005) 1.10
A PROMIS fatigue short form for use by individuals who have multiple sclerosis. Qual Life Res (2011) 1.09
Spinocerebellar ataxia type 14 caused by a mutation in protein kinase C gamma. Arch Neurol (2003) 1.08
Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). Mov Disord (2004) 1.06
Wnt/β-catenin signaling suppresses DUX4 expression and prevents apoptosis of FSHD muscle cells. Hum Mol Genet (2013) 1.06
The magnetic resonance imaging spectrum of facioscapulohumeral muscular dystrophy. Muscle Nerve (2012) 1.06
The efficacy of telephone counseling for health promotion in people with multiple sclerosis: a randomized controlled trial. Arch Phys Med Rehabil (2008) 1.04
A comparison of self-hypnosis versus progressive muscle relaxation in patients with multiple sclerosis and chronic pain. Int J Clin Exp Hypn (2009) 1.04
SIMPLE mutation in demyelinating neuropathy and distribution in sciatic nerve. Ann Neurol (2004) 1.03
Frequency of KCNC3 DNA variants as causes of spinocerebellar ataxia 13 (SCA13). PLoS One (2011) 1.03
Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant (2010) 1.02
Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. Arch Neurol (2011) 1.01
Heritability of different forms of memory in the Late Onset Alzheimer's Disease Family Study. J Alzheimers Dis (2011) 1.01
Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease. Alzheimers Dement (2008) 1.00
Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation. Neurosci Lett (2010) 1.00
Familial dementia with lewy bodies: a clinical and neuropathological study of 2 families. Arch Neurol (2002) 0.99
Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases). Clin Immunol (2004) 0.99
Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol (2008) 0.98
Beyond fatigue: Assessing variables associated with sleep problems and use of sleep medications in multiple sclerosis. Clin Epidemiol (2010) 0.98
Pain in youths with neuromuscular disease. Am J Hosp Palliat Care (2009) 0.98
Familial dyskinesia and facial myokymia (FDFM): Follow-up of a large family and linkage to chromosome 3p21-3q21. Am J Med Genet B Neuropsychiatr Genet (2009) 0.97
Effects of self-hypnosis training and cognitive restructuring on daily pain intensity and catastrophizing in individuals with multiple sclerosis and chronic pain. Int J Clin Exp Hypn (2011) 0.97
Satisfaction with, and the beneficial side effects of, hypnotic analgesia. Int J Clin Exp Hypn (2006) 0.97
Longitudinal features of STIR bright signal in FSHD. Muscle Nerve (2014) 0.97
Lewy body pathology in late-onset familial Alzheimer's disease: a clinicopathological case series. J Alzheimers Dis (2006) 0.96
The amyotrophic lateral sclerosis center: a model of multidisciplinary management. Phys Med Rehabil Clin N Am (2008) 0.96
Alteration in calcium channel properties is responsible for the neurotoxic action of a familial frontotemporal dementia tau mutation. J Neurochem (2003) 0.96
Early-onset Alzheimer disease in families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease. Arch Neurol (2006) 0.95
Altered splicing of ATP6AP2 causes X-linked parkinsonism with spasticity (XPDS). Hum Mol Genet (2013) 0.95
Conjugal Alzheimer disease: risk in children when both parents have Alzheimer disease. Arch Neurol (2008) 0.95
Unusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome. Mod Pathol (2004) 0.95
Long-term outcome of hypnotic-analgesia treatment for chronic pain in persons with disabilities. Int J Clin Exp Hypn (2008) 0.94
CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Ann Neurol (2013) 0.94
A novel mutation in FHL1 in a family with X-linked scapuloperoneal myopathy: phenotypic spectrum and structural study of FHL1 mutations. J Neurol Sci (2010) 0.94
Impact of biopsychosocial factors on chronic pain in persons with myotonic and facioscapulohumeral muscular dystrophy. Am J Hosp Palliat Care (2009) 0.93
Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease. J Neuropathol Exp Neurol (2010) 0.93
Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates. Hum Mol Genet (2009) 0.91
Neuronal loss in Pelizaeus-Merzbacher disease differs in various mutations of the proteolipid protein 1. Acta Neuropathol (2009) 0.91
Coping with chronic pain among younger, middle-aged, and older adults living with neurological injury and disease. J Aging Health (2008) 0.91
Evidence for three loci modifying age-at-onset of Alzheimer's disease in early-onset PSEN2 families. Am J Med Genet B Neuropsychiatr Genet (2010) 0.90
The reliability and validity of a self-report version of the FIM instrument in persons with neuromuscular disease and chronic pain. Arch Phys Med Rehabil (2005) 0.90
Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry (2007) 0.89